ADC Therapeutics SA (ADCT)

USD 1.44

(0.7%)

Long Term Debt Summary of ADC Therapeutics SA

  • ADC Therapeutics SA's latest annual long term debt in 2023 was 112.73 Million USD , up 8.6% from previous year.
  • ADC Therapeutics SA's latest quarterly long term debt in 2024 Q2 was 113.67 Million USD , up 0.39% from previous quarter.
  • ADC Therapeutics SA reported annual long term debt of 103.8 Million USD in 2022, up 10.26% from previous year.
  • ADC Therapeutics SA reported annual long term debt of 94.14 Million USD in 2021, up 152.81% from previous year.
  • ADC Therapeutics SA reported quarterly long term debt of 113.67 Million USD for 2024 Q2, up 0.39% from previous quarter.
  • ADC Therapeutics SA reported quarterly long term debt of 107.78 Million USD for 2023 Q3, down -0.31% from previous quarter.

Annual Long Term Debt Chart of ADC Therapeutics SA (2023 - 2016)

Historical Annual Long Term Debt of ADC Therapeutics SA (2023 - 2016)

Year Long Term Debt Long Term Debt Growth
2023 112.73 Million USD 8.6%
2022 103.8 Million USD 10.26%
2021 94.14 Million USD 152.81%
2020 37.24 Million USD 855.12%
2019 3.89 Million USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%

Peer Long Term Debt Comparison of ADC Therapeutics SA

Name Long Term Debt Long Term Debt Difference
Alto Neuroscience, Inc. 151.33 Million USD 25.511%
Annovis Bio, Inc. - USD -Infinity%
Biohaven Pharmaceutical Holding Company Ltd. 27.56 Million USD -308.901%
Ginkgo Bioworks Holdings, Inc. 221.83 Million USD 49.183%
Nuvation Bio Inc. 2.03 Million USD -5439.558%
Nuvation Bio Inc. 2.03 Million USD -5439.558%
Arcus Biosciences, Inc. 110 Million USD -2.482%
Zymeworks Inc. 22.46 Million USD -401.892%